This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. reported that director Jake Simson received a grant of stock options covering 15,000 shares of common stock at an exercise price of $37.34 per share. The options vest in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided he continues to serve until that date.
Under an arrangement with RA Capital Management, L.P., Simson holds this option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. Any net cash or stock from exercising the option must be turned over to the adviser to offset advisory fees, and Simson disclaims beneficial ownership of the option and underlying shares.
Septerna, Inc. held its 2026 annual meeting of stockholders on June 26, 2026. Stockholders elected Shalini Sharp, M.B.A. and Jake Simson, Ph.D. as Class II directors to serve three-year terms ending at the 2029 annual meeting and until their successors are elected and qualified or earlier departure.
Sharp received 33,732,317 votes for and 5,808,264 votes withheld, while Simson received 33,716,857 votes for and 5,823,724 votes withheld. Stockholders also ratified Ernst & Young LLP as Septerna’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 41,207,237 votes for, 4,008 against, and 298,811 abstentions.
SEPN Rule 144 notice: The filing lists proposed transactions in Common stock under an Employee Stock Purchase Plan and a Rule 144 notice dated 06/26/2026. It shows a reported sale by JAE KIM of 94,339 shares on 06/22/2026 for $3,326,119.56. The excerpt also lists plan-related entries dated 10/31/2025 (1,198 shares) and 04/30/2026 (1,240 shares).
Septerna, Inc. SVP of Drug Discovery Daniel D. Long reported option exercises and share sales in SEPN stock. On June 22, 2026, he exercised options for 4,471 shares at $11.70 per share and 10,529 shares at $2.76 per share, converting them into common stock.
On the same date, he sold 7,000 shares at a weighted average price of $35.9687 and 8,000 shares at $35.1001 in open-market transactions under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 96,412 shares of common stock.
Septerna, Inc. Chief People Officer Samira Shaikhly reported an exercise-and-sale transaction in company stock. On June 12, 2026, she exercised options to acquire 6,250 shares of common stock at $11.70 per share, then sold 6,250 shares in an open-market transaction at a weighted average price of $35.0759 per share, with individual sale prices ranging from $35.00 to $35.19. These trades were executed under a pre-arranged Rule 10b5-1 sales plan. Following the transactions, she directly holds 793 shares of common stock and 23,750 stock options that remain outstanding and are scheduled to expire on August 6, 2035, continuing to give her equity exposure to Septerna’s future performance.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting an intended sale of 8,428 shares of Common Stock on 06/12/2026 arising from an exercise of stock options with cash used as the method of payment. The filing also lists recent 10b5-1 sales by Samira Shaikhly: 5,935 shares on 06/01/2026 and 11,798 shares on 05/26/2026.
Septerna, Inc.’s Chief People Officer Samira Shaikhly reported an exercise-and-sell sequence in company stock. She exercised options to acquire 5,935 shares of common stock at exercise prices of $1.55 and $2.76 per share, then sold 5,935 shares in open-market transactions at weighted average prices of $27.78, $28.79 and $29.66 per share, within ranges from $27.24 to $30.08. The sales were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025.
Septerna, Inc. Chief People Officer Samira Shaikhly reported an option exercise and related share sale. She exercised stock options to acquire 11,798 shares of common stock at an exercise price of $6.81 per share, then sold 11,798 shares in open-market transactions at a weighted average price of $30.0607 per share.
The sales were made under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025, and executed in multiple trades between $30.00 and $30.24 per share. After these transactions, she directly owned 793 shares of Septerna common stock.